A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2002
08/22/2002	WO2002064609A1 Crystal of pyrimidine nucleoside derivative
08/22/2002	WO2002064603A1 Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields
08/22/2002	WO2002064601A1 Dicarba-closo-dodecarborane derivatives
08/22/2002	WO2002064599A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors
08/22/2002	WO2002064598A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
08/22/2002	WO2002064595A1 Triazolo compounds as mmp inhibitors
08/22/2002	WO2002064594A2 6-substituted pyrido-pyrimidines
08/22/2002	WO2002064593A1 2-alkoxyphenyl substituted imidazotriazinones
08/22/2002	WO2002064592A1 Tricyclic crf receptor antagonists
08/22/2002	WO2002064591A2 Carboline derivatives
08/22/2002	WO2002064590A2 Carboline derivatives
08/22/2002	WO2002064589A1 Laulimalide derivatives
08/22/2002	WO2002064586A2 Heterocyclic inhibitors of erk2 and uses thereof
08/22/2002	WO2002064584A1 Phthalayinone-piperidino-derivatives as pde4 inhibitors
08/22/2002	WO2002064581A1 4-aminobenzopyran derivatives
08/22/2002	WO2002064580A1 Lactone compounds as novel photoinitiators
08/22/2002	WO2002064578A1 Benzo thiadiazine matrix metalloproteinase inhibitors
08/22/2002	WO2002064576A1 Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
08/22/2002	WO2002064575A1 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolins and the utilization thereof as anticoagulant and antithrombotic agents
08/22/2002	WO2002064574A2 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods
08/22/2002	WO2002064572A1 Quinazolines as mmp-13 inhibitors
08/22/2002	WO2002064571A1 Pyrimidine matrix metalloproteinase inhibitors
08/22/2002	WO2002064570A1 Novel alkyl phenylimino-imidazolidine derivatives for treating urinary incontinence
08/22/2002	WO2002064568A1 Pyridine matrix metalloproteinase inhibitors
08/22/2002	WO2002064565A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical
08/22/2002	WO2002064564A1 Benzo'f!isoindole derivatives with affinity to the ep4 receptor
08/22/2002	WO2002064563A1 Novel benzoylguanidine salt
08/22/2002	WO2002064559A2 Thrombin inhibitors
08/22/2002	WO2002064557A2 New crystal forms of oxcarbazepine and processes for their preparation
08/22/2002	WO2002064552A1 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
08/22/2002	WO2002064550A1 Glucocorticoid receptor modulators
08/22/2002	WO2002064549A1 Ppar agonists
08/22/2002	WO2002064547A2 Isophthalic acid derivatives as matrix metalloproteinase inhibitors
08/22/2002	WO2002064546A2 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
08/22/2002	WO2002064545A1 Acylated indanyl amines and their use as pharmaceuticals
08/22/2002	WO2002064543A2 Novel succinate salt of o-desmethyl-venlafaxine
08/22/2002	WO2002064214A2 Anti cancer combination of substituted pyrroles and paclitaxel
08/22/2002	WO2002064213A1 Use of flumazenil to produce a medicament for the treatment of cocaine dependency
08/22/2002	WO2002064212A1 Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist
08/22/2002	WO2002064211A1 Thrombin inhibitors
08/22/2002	WO2002064210A2 Combination therapy comprising anti-diabetic and anticonvulsant agents
08/22/2002	WO2002064189A2 Radiation cross-linked hydrogels
08/22/2002	WO2002064169A1 Methods of treating diseases in association with decrease in the expression of aop-1 gene or aop-1 and remedies for the diseases
08/22/2002	WO2002064168A1 Targetted anti-tumor drug delivery systems
08/22/2002	WO2002064160A2 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
08/22/2002	WO2002064157A2 Localized myocardial injection method for treating ischemic myocardium
08/22/2002	WO2002064151A1 Acrochordon alleviation
08/22/2002	WO2002064149A1 Method for the prevention of tissue elastic fiber injury
08/22/2002	WO2002064148A2 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
08/22/2002	WO2002064147A1 Antibiotic compositon and method
08/22/2002	WO2002064146A1 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
08/22/2002	WO2002064144A1 Aqueous suspension eyedrops and process for producing the same
08/22/2002	WO2002064143A1 Medicinal composition for treatment of chronic cardiac failure
08/22/2002	WO2002064142A1 Farnesyl protein transferase inhibitor combinations with antiestrogen agents
08/22/2002	WO2002064141A1 New use of iloperidone
08/22/2002	WO2002064140A1 Thrombin inhibitors
08/22/2002	WO2002064139A1 Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
08/22/2002	WO2002064138A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
08/22/2002	WO2002064137A1 Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes
08/22/2002	WO2002064136A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
08/22/2002	WO2002064135A1 Heterocyclic inhibitors of glycine transporter 2
08/22/2002	WO2002064134A2 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
08/22/2002	WO2002064133A1 Preparations for controlling concentration in blood
08/22/2002	WO2002064132A2 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
08/22/2002	WO2002064131A2 Inflammation-inhibiting compounds
08/22/2002	WO2002064130A1 Proliferative activator receptor (ppar) compounds
08/22/2002	WO2002064129A2 Compositions of biochemical compounds involved in bioenergy metabolism of cells
08/22/2002	WO2002064128A1 Treatment of diseases characterized by excessive or insufficient cell death
08/22/2002	WO2002064127A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth
08/22/2002	WO2002064126A2 Method of treating of demyelinating diseases or conditions
08/22/2002	WO2002064125A2 Use of a farnesoid x receptor antagonist for treating hyperlipidemia
08/22/2002	WO2002064124A2 Medicament formulation containing a muscarinic agonist
08/22/2002	WO2002064121A1 Novel modified released formulation
08/22/2002	WO2002064119A1 Tablets quickly disintegrated in oral cavity
08/22/2002	WO2002064118A1 Novel modified release formulation
08/22/2002	WO2002064113A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
08/22/2002	WO2002064111A1 Vitamin/mineral complex
08/22/2002	WO2002064110A2 Carotenoid-loaded liposomes
08/22/2002	WO2002064109A2 Mucoadhesive pharmaceutical formulations
08/22/2002	WO2002064096A2 Methods of using pyrimidine-based antiviral agents
08/22/2002	WO2002064094A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
08/22/2002	WO2002064093A2 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
08/22/2002	WO2002064092A2 Method for evaluating therapeutic efficacy
08/22/2002	WO2002064087A2 Neurotherapeutic use of carboxypeptidase inhibitors
08/22/2002	WO2002064085A2 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
08/22/2002	WO2002064083A2 Synthesis of 3-amino-thalidomide and its enantiomers
08/22/2002	WO2002064080A2 Matrix metalloproteinase inhibitors
08/22/2002	WO2002064064A1 Injectable pharmaceutical composition comprising microparticles or microdroplets of camptothecin
08/22/2002	WO2002064046A2 A compound and method of treatment for fungal pathologies of the oral cavity
08/22/2002	WO2002064026A2 Treating pulmonary disorders with gaseous agent causing repletion of gsno
08/22/2002	WO2002064022A2 Therapy for cerebral vasospasm
08/22/2002	WO2002064014A2 Endomural therapy
08/22/2002	WO2002063982A1 Composition and method for smoke detoxification
08/22/2002	WO2002063976A1 Food product comprising soy protein and statins
08/22/2002	WO2002063961A1 Composition and methods for modulation of vascular structure and/or function
08/22/2002	WO2002063954A2 USE OF β-LACTAMASE INHIBITORS AS NEUROPROTECTANTS
08/22/2002	WO2002053139A3 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
08/22/2002	WO2002050125A3 Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation
08/22/2002	WO2002048112A3 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone
08/22/2002	WO2002047534A3 Compositions and methods for the therapy and diagnosis of lung cancer

1 ... 5731 5732 5733 5734 5735 5736 5737 5738 5739 5740 5741 5742 5743 5744 5745 5746 5747 5748 5749 5750 5751 ... 7860